These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 39163733)

  • 1. TP53 mutations and survival in patients with histologically defined Glioblastoma, IDH-wildtype.
    Di Nunno V; Gatto L; Tosoni A; Aprile M; Galvani L; Zappi A; Foschini MP; Asioli S; Tallini G; De Biase D; Maloberti T; Bartolini S; Giannini C; Franceschi E
    Pathol Res Pract; 2024 Oct; 262():155516. PubMed ID: 39163733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
    Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M
    Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations.
    Hartmann C; Hentschel B; Simon M; Westphal M; Schackert G; Tonn JC; Loeffler M; Reifenberger G; Pietsch T; von Deimling A; Weller M;
    Clin Cancer Res; 2013 Sep; 19(18):5146-57. PubMed ID: 23918605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Partial resection offers an overall survival benefit over biopsy in MGMT-unmethylated IDH-wildtype glioblastoma patients.
    Hallaert G; Pinson H; Vanhauwaert D; Van den Broecke C; Van Roost D; Boterberg T; Kalala JP
    Surg Oncol; 2020 Dec; 35():515-519. PubMed ID: 33152608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR amplification is a real independent prognostic impact factor between young adults and adults over 45yo with wild-type glioblastoma?
    Armocida D; Pesce A; Frati A; Santoro A; Salvati M
    J Neurooncol; 2020 Jan; 146(2):275-284. PubMed ID: 31889239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Negative prognostic impact of epidermal growth factor receptor copy number gain in young adults with isocitrate dehydrogenase wild-type glioblastoma.
    Hoffman DI; Abdullah KG; McCoskey M; Binder ZA; O'Rourke DM; Desai AS; Nasrallah MP; Bigdeli A; Morrissette JJD; Brem S; Bagley SJ
    J Neurooncol; 2019 Nov; 145(2):321-328. PubMed ID: 31542863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low MGMT digital expression is associated with a better outcome of IDH1 wildtype glioblastomas treated with temozolomide.
    Gomes I; Moreno DA; Dos Reis MB; da Silva LS; Leal LF; Gonçalves GM; Pereira CA; Oliveira MA; de Medeiros Matsushita M; Reis RM
    J Neurooncol; 2021 Jan; 151(2):135-144. PubMed ID: 33400009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MGMT methylation and its prognostic significance in inoperable IDH-wildtype glioblastoma: the MGMT-GBM study.
    Ghimire P; Kamaludin A; Palau BF; Lavrador JP; Gullan R; Vergani F; Bhangoo R; Ashkan K
    Acta Neurochir (Wien); 2024 Oct; 166(1):394. PubMed ID: 39367282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age-stratified clinical performance and survival of patients with IDH-wildtype glioblastoma homogeneously treated by radiotherapy with concomitant and maintenance temozolomide.
    Berger K; Turowski B; Felsberg J; Malzkorn B; Reifenberger G; Steiger HJ; Budach W; Haussmann J; Knipps J; Rapp M; Hänggi D; Sabel M; Mijderwijk HJ; Kamp MA
    J Cancer Res Clin Oncol; 2021 Jan; 147(1):253-262. PubMed ID: 32748120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas.
    Christians A; Adel-Horowski A; Banan R; Lehmann U; Bartels S; Behling F; Barrantes-Freer A; Stadelmann C; Rohde V; Stockhammer F; Hartmann C
    Acta Neuropathol Commun; 2019 Oct; 7(1):156. PubMed ID: 31623667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Correlates of Long Survival in IDH-Wildtype Glioblastoma Cohorts.
    Galbraith K; Kumar A; Abdullah KG; Walker JM; Adams SH; Prior T; Dimentberg R; Henderson FC; Mirchia K; Sathe AA; Viapiano MS; Chin LS; Corona RJ; Hatanpaa KJ; Snuderl M; Xing C; Brem S; Richardson TE
    J Neuropathol Exp Neurol; 2020 Aug; 79(8):843-854. PubMed ID: 32647886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation.
    Wang K; Wang YY; Ma J; Wang JF; Li SW; Jiang T; Dai JP
    Asian Pac J Cancer Prev; 2014; 15(24):10893-8. PubMed ID: 25605197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arterial spin labeling perfusion-weighted imaging aids in prediction of molecular biomarkers and survival in glioblastomas.
    Yoo RE; Yun TJ; Hwang I; Hong EK; Kang KM; Choi SH; Park CK; Won JK; Kim JH; Sohn CH
    Eur Radiol; 2020 Feb; 30(2):1202-1211. PubMed ID: 31468161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.
    Weller M; Felsberg J; Hartmann C; Berger H; Steinbach JP; Schramm J; Westphal M; Schackert G; Simon M; Tonn JC; Heese O; Krex D; Nikkhah G; Pietsch T; Wiestler O; Reifenberger G; von Deimling A; Loeffler M
    J Clin Oncol; 2009 Dec; 27(34):5743-50. PubMed ID: 19805672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aggressive Treatment in Glioblastoma: What Determines the Survival of Patients?
    Yu L; Zhang G; Qi S
    J Neurol Surg A Cent Eur Neurosurg; 2021 Mar; 82(2):112-117. PubMed ID: 33157564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline ALK variations are associated with a poor prognosis in glioma and IDH-wildtype glioblastoma.
    Bu L; Hameed NUF; Luo C; Hong P; Zhou X; Wang S; Wu S
    J Neurooncol; 2021 Mar; 152(1):27-36. PubMed ID: 33486679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations.
    Arita H; Matsushita Y; Machida R; Yamasaki K; Hata N; Ohno M; Yamaguchi S; Sasayama T; Tanaka S; Higuchi F; Iuchi T; Saito K; Kanamori M; Matsuda KI; Miyake Y; Tamura K; Tamai S; Nakamura T; Uda T; Okita Y; Fukai J; Sakamoto D; Hattori Y; Pareira ES; Hatae R; Ishi Y; Miyakita Y; Tanaka K; Takayanagi S; Otani R; Sakaida T; Kobayashi K; Saito R; Kurozumi K; Shofuda T; Nonaka M; Suzuki H; Shibuya M; Komori T; Sasaki H; Mizoguchi M; Kishima H; Nakada M; Sonoda Y; Tominaga T; Nagane M; Nishikawa R; Kanemura Y; Kuchiba A; Narita Y; Ichimura K
    Acta Neuropathol Commun; 2020 Nov; 8(1):201. PubMed ID: 33228806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IDH-wild type glioblastomas featuring at least 30% giant cells are characterized by frequent RB1 and NF1 alterations and hypermutation.
    Barresi V; Simbolo M; Mafficini A; Martini M; Calicchia M; Piredda ML; Ciaparrone C; Bonizzato G; Ammendola S; Caffo M; Pinna G; Sala F; Lawlor RT; Ghimenton C; Scarpa A
    Acta Neuropathol Commun; 2021 Dec; 9(1):200. PubMed ID: 34952640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of Survival in Turkish Patients with Primary Glioblastoma.
    Bilgin E; Duman BB; Altintas S; Cil T; Gezercan Y; Okten AI
    Turk Neurosurg; 2021; 31(4):641-653. PubMed ID: 33759174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IDH-Mutation Is a Weak Predictor of Long-Term Survival in Glioblastoma Patients.
    Amelot A; De Cremoux P; Quillien V; Polivka M; Adle-Biassette H; Lehmann-Che J; Françoise L; Carpentier AF; George B; Mandonnet E; Froelich S
    PLoS One; 2015; 10(7):e0130596. PubMed ID: 26158269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.